慢性肾疾病继发性甲状旁腺功能亢进的治疗现状及研究

www.yongyao.net　　2009-7-21 10:19:03　　来源：　　责任编辑：

分享到：

参考文献
[ 1 ] 　Slatopolsky E,Dusso A, Brown AJ. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cellp roliferation in chronic renal failure[ J ]. Am J Med Sci, 1999, 3176) : 3702376.
[ 2 ] 　Chertow G,Burke S,DillonM, et al. Long term effects of sevelamer hydrochloride on the calcium ×phosphate p roduct and lip id p rofile of haemodialysis patients [ J ]. Nephrol Dial Transp lant, 1999, 14(12) : 290722914.
[ 3 ] 　Albaaj F, Hutchison AJ. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients[ J ]. Expert Op in Pharmacother, 2005, 6 (2) : 3192328.
[ 4 ] 　Mucsi I, Hercz G,Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis[ J ]. Kidney Int, 1998, 53 (5) : 139921404.
[ 5 ] 　Lugon JR,Andre ME, Duarte ME, et al. Effects of in center daily hemodialysis upon mineral metabolism and bone disease in end stage renal disease patients[ J ]. Sao PauloMed J, 2001, 119 (3) :1052109.
[ 6 ] 　BoranM,Doruk E, Gonenc F, et al. 1, 25 (OH) 2 cholecalciferol pulse therapy and the effects of different dialysismembranes on serum PTH levels of hemodialysis patients [ J ]. Int Urol Nephrol,1997, 29 (2) : 2512258.
[ 7 ] 　Foley RN, Parfrey PS, Harnett JD, et al. Hypocalcemia, morbidity,and mortality in end 2 stage renal disease [ J ]. Am J Nephrol,1996, 16 (5) : 3862393.
[ 8 ] 　GoodmanWG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers p lasma parathyroid hormone levels in patientswith secondary hyperparathyroidism[ J ]. Kidney Int, 2000, 58 (1) : 4362445.
[ 9 ] 　GoodmanWG. Renal osteodystrophy: p resent and future [ J ]. ClinExp Nehrol, 2000, 4 (6) : 1822188.
[ 10 ] 　Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely supp resses parathyroid hormone levels in patientswith chronic renal failure[ J ]. Kidney Int, 1998, 53 (1) : 2232227.
[ 11 ] 　Fischer ER, HarrisDC. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperpara thyroidism[ J ]. Clin Nephrol, 1993, 40 (4) : 2162220.
[ 12 ] 　Gallagher JC. Pathophysiology of osteoporosis[ J ]. Semin Nephrol,1992, 12 (2) : 1092115.
[ 13 ] 　SchroederNJ, Cunningham J. What′s new in vitamin D for the nephrologist ? [ J ]. Nephrol Dial Transp lant, 2000, 15 ( 12 ) :4602466.
[ 14 ] 　Fan SL, Cunningham J. Bisphosphonates in renal osteodystrophy[ J ]. CurrOp in Nephrol Hypertens, 2001, 10 (5) : 5812588.
[ 15 ] 　Kotzmann H, RiedlM, Pietschmann P, et al. Effects of 12 months of recombinant growth hormone therapy on parameters of bone mineral density in patients on chronic hemodialysis [ J ]. J Nephrol, 2004,17 (1) : 87294.
[ 16 ] 　Li T, Surendran K, Zawaideh MA, et al. Bone morphogenetic p rotein 7: a novel treatment for chronic renal and bone disease [ J ].CurrOp in Nephrol Hypertens, 2004, 13 (4) : 4172422.
[ 17 ] 　Fukagawa M, Tominaga Y, Kitaoka M, et al. Medical and surgical aspects of parathyroidectomy [ J ]. Kidney Int Supp l, 1999, 73:S652S69.
[ 18 ] 　Fabretti F, Calabrese V, Fornasari V, et al. Subtotal parathyroidec tomy for secondary hyperparathyroidism in chronic renal failure[ J ]. J Laryngol Otol, 1991, 105 (7) : 5622567.